Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785631 | 0.98 | TRPV3 (0.39) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785642 | 0.92 | SCN10A (0.40) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785636 | 0.90 | SCN10A (0.42) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785570 | 0.90 | TRPV3 (0.39) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785543 | 0.89 | HTR2C (0.39) | TRPV3MAP4K4EIF2AK4KMT2ABTK | |
| SCHEMBL16785645 | 0.89 | TRPV3 (0.40) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785633 | 0.86 | HTR2C (0.39) | TRPV3MAP4K4EIF2AK4KMT2ABTK | |
| SCHEMBL16785632 | 0.85 | TRPV3 (0.39) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 | |
| SCHEMBL16785539 | 0.85 | TRPV3 (0.41) | TRPV3SCN10AMAP4K4EIF2AK4KMT2A | |
| SCHEMBL16785626 | 0.84 | POLB (0.39) | TRPV3DGAT2SCN10AMAP4K4EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | TRPV3 4093/4885DGAT2 1047/4885SCN10A 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.